Ipca Lab’s revenue in Q2FY19 grew 15.4% yoy to Rs997.8cr. The performance was all around with domestic business growing 10% yoy and exports up 21.6% yoy in Q2FY19. EBITDA grew by 15.7% yoy to Rs172.8cr in Q2FY19 vs. Rs149.4cr in Q2FY18. EBITDA margins stood at 17.3% in Q2FY19 (unchanged yoy) vs. 13.4% in Q1FY19. PAT grew by 24.1% yoy to Rs119.7cr in Q2FY19 vs. Rs96.5cr in Q2FY18.
Gross margins witnessed strong recovery and improved by 112bps qoq and 272bps yoy to 68.6% in Q2FY19.
Domestic formulations revenue grew by 10.3% yoy to Rs468.6cr while domestic API revenue grew by 7.5% yoy to Rs51.4cr in Q2FY19.
Exports formulations grew by 23.2% yoy to Rs288.3cr in Q2FY19.
Exports API revenue grew by 19% yoy to Rs173.7cr in Q2FY19.
In Q2FY19, domestic business contributed 53% of revenue, while rest 47% was contributed by exports.
Ipca Laboratories Ltd is currently trading at Rs. 736.50, up by 12.7 points or 1.75% from its previous closing of Rs. 723.80 on the BSE.
The scrip opened at Rs. 723.60 and has touched a high and low of Rs. 737.90 and Rs. 709.30 respectively. So far 2,94,584 (NSE+BSE) shares were traded on the counter. The stock is currently trading below its 100 DMA.
Start investing in Equities, Derivatives, Mutual Funds and Currency
Temporary Password will be sent to your Mobile No. / Email Address to reset your password.
Make smart financial decisions
Trusted by more than 25 Lakhs Indians
Research and Stocks
Strategy and Tools
Terms & Conditions
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in National Do Not Call Registry as laid down by Telecom Regulatory Authority of India will not be applicable for such information/ communication.